Mini Review
Volume 9 Issue 6 - 2022
Common Errors in H. Pylori Management - Recommendations for an Improved Practice
Rabbia Tariq, Sarush Ahmed Siddiqui*, Ariba Moin, Hiba Ahmed, Maheen Tariq, Alina Moin, Imad Uddin Sawal, Muhammad Faizan Yousuf, Fahad Hassan Shaikh and Shajie UR Rehman Usmani
Department of Internal Medicine, Dow University of Health Sciences, Pakistan
*Corresponding Author: Sarush Ahmed Siddiqui, Department of Internal Medicine, Dow University of Health Sciences, Pakistan.
Received: April 26, 2022; Published: May 24, 2022




Abstract

Helicobacter pylori (H pylori) infection affects half of the world’s population and accounts for 90% of all gastric cancers. This alarming situation is a byproduct of increasing antibiotic resistance due to which many previously successful therapies have been rendered ineffective. A major challenge that stands in the way of H pylori eradication is the inept and delayed implementation of clinical guidelines, creating a gap between scientific recommendations and actual clinical practice. This review highlights the discrepancies in guideline implementation and common errors that are made by practitioners while prescribing therapy. These errors include prescribing triple therapy instead of quadruple regimen as first-line therapy, repeating antibiotics in subsequent therapies, prescribing therapy for 7 - 10 days instead of 14 days, prescribing a low-dose of proton pump inhibitors (PPIs), not checking eradication success and failing to consider the importance of treatment compliance. This review also outlines some recommendations for the practitioners to overcome these prevailing errors in treatment, as well as some suggestions for the healthcare authorities to actively disseminate the clinical guidelines and ensure that they are meticulously implemented.

 

Keywords: Helicobacter pylori; Antibiotic Resistance; Holistic Therapy; Treatment Compliance

References

  1. Selgrad M and Malfertheiner P. “Management of Helicobacter pylori infection: what should the surgeon know”. Visceral Medicine3 (2017): 216-219.
  2. Sharara AI. “Confirmatory Testing for Eradication of Helicobacter pylori: Challenges and Opportunities”. Clinical Gastroenterology and Hepatology2 (2020): 232-234.
  3. Flores-Treviño S., et al. “Helicobacter pylori drug resistance: therapy changes and challenges”. Expert Review of Gastroenterology and Hepatology8 (2018): 819-827.
  4. Zou Y., et al. “The effect of antibiotic resistance on Helicobacter pylori eradication efficacy: A systematic review and meta‐analysis”. Helicobacter4 (2020): e12714.
  5. Gisbert JP., et al. “IV Spanish Consensus Conference on Helicobacter pylori infection treatment”. Gastroenterología y Hepatología10 (2016): 697-721.
  6. Malfertheiner P., et al. “Management of Helicobacter pylori infection-the Maastricht V/Florence consensus report”. Gut1 (2017): 6-30.
  7. Chey WD., et al. “ACG clinical guideline: treatment of Helicobacter pylori infection”. Official Journal of the American College of Gastroenterology| ACG2 (2017): 212-239.
  8. McNicholl AG., et al. “Spanish Primary Care Societies SEMFyC, SEMERGEN and SEMG, the Spanish Association of Gastroenterology and OPTICARE Long‐Term Educational Project, 2019. Spanish primary care survey on the management of Helicobacter pylori infection and dyspepsia: Information, attitudes, and decisions”. Helicobacter4 (2019): e12593.
  9. Na’amnih W., et al. “Physicians’ adherence to management guidelines for H. pylori infection and gastroesophageal reflux disease: a cross-sectional study”. Israel Journal of Health Policy Research1 (2020): 1-7.
  10. Song C., et al. “Management of Helicobacter pylori infection by clinicians: a nationwide survey in a developing country”. Helicobacter6 (2019): e12656.
  11. Cabana MD., et al. “Why don't physicians follow clinical practice guidelines?: A framework for improvement”. The Journal of the American Medical Association15 (1999): 1458-1465.
  12. Fischer F., et al. “Barriers and strategies in guideline implementation-a scoping review”. InHealthcare Multidisciplinary Digital Publishing Institute3 (2016): 36.
  13. De Wit NJ., et al. “Guidelines on the management of H. pylori in primary care: development of an implementation strategy”. Family Practice2 (2000): S27-s32.
  14. Poonyam P., et al. “High effective of 14-day high-dose PPI-Bismuth-containing quadruple therapy with probiotics supplement for Helicobacter pylori eradication: a double blinded-randomized placebo-controlled study”. Asian Pacific Journal of Cancer Prevention: APJCP9 (2019): 2859.
  15. Gisbert JP and Calvet X. “Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough”. Alimentary Pharmacology and Therapeutics 11-12 (2011): 1255-1268.
  16. Venerito M., et al. “Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection”. Digestion1 (2013): 33-45.
  17. Kekilli M., et al. “Inefficacy of triple therapy and comparison of two different bismuth-containing quadruple regimens as a firstline treatment option for helicobacter pylori”. Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association5 (2016): 366.
  18. Malfertheiner P., et al. “Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report”. Gut6 (2007): 772-781.
  19. Gisbert JP., et al. “Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy”. Digestive Diseases and Sciences2 (2015): 458-464.
  20. Nyssen OP., et al. “Room for Improvement in the Treatment of Helicobacter pylori Infection: Lessons from the European Registry on H. pylori Management (Hp-EuReg)”. Journal of Clinical Gastroenterology (2021).
  21. Boltin D., et al. “Attitudes and practice related to Helicobacter pylori infection among primary care physicians”. European Journal of Gastroenterology and Hepatology9 (2016): 1035-1040.
  22. Jukic I., et al. “Adherence to Maastricht V/Florence consensus report for the management of Helicobacter pylori infection among primary care physicians and medical students in Croatia: A cross‐sectional study”. Helicobacter 23 (2020): e12775.
  23. Chuah YY., et al. “Real‐world practice and Expectation of Asia‐Pacific physicians and patients in Helicobacter Pylori eradication (REAP‐HP Survey)”. Helicobacter3 (2017): e12380.
  24. Kim BG., et al. “Discrepancies between primary physician practice and treatment guidelines for Helicobacter pylori infection in Korea”. World Journal of Gastroenterology: WJG1 (2006): 66.
  25. Murakami TT., et al. “Management of Helicobacter Pylori in the United States: results from a national survey of gastroenterology physicians”. Preventive Medicine 100 (2017): 216-222.
  26. Miehlke S., et al. “Diagnostic and therapeutic management of Helicobacter pylori infection: a survey among resident gastroenterologists in Germany”. Zeitschrift für Gastroenterologie10 (2016): 1130-1137.
  27. Jheng GH., et al. “Comparison of second-line quadruple therapies with or without bismuth for Helicobacter pylori infection”. BioMed Research International (2015).
  28. Chen YI and Fallone CA. “A 14-day course of triple therapy is superior to a 10-day course for the eradication of Helicobacter pylori: a Canadian study conducted in a ‘real world’setting”. Canadian Journal of Gastroenterology and Hepatology8 (2015): e7-10.
  29. Puig I., et al. “Fourteen‐day high‐dose esomeprazole, amoxicillin and metronidazole as third‐line treatment for Helicobacter pylori infection”. International Journal of Clinical Practice9 (2017): e13004.
  30. Calvet X. “Dealing with uncertainty in the treatment of Helicobacter pylori”. Therapeutic Advances in Chronic Disease4 (2018): 93-102.
  31. Yuan Y., et al. “Optimum duration of regimens for Helicobacter pylori eradication”. Cochrane Database of Systematic Reviews 12 (2013).
  32. Kim TH., et al. “Comparison of 7-and 14-day eradication therapy for Helicobacter pylori with first-and second-line regimen: randomized clinical trial”. Journal of Korean Medical Science5 (2020).
  33. Cano-Contreras AD., et al. “The approach, attitudes and knowledge about Helicobacter pylori in general practitioners is deficient. There is much to improve”. Revista de Gastroenterología de México1 (2018): 16-24.
  34. Villoria A., et al. “Meta‐analysis: high‐dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication”. Alimentary Pharmacology and Therapeutics7 (2008): 868-877.
  35. Kositchaiwat C., et al. “Low and high doses of rabeprazole vs. omeprazole for cure of Helicobacter pylori infection”. Alimentary Pharmacology and Therapeutics10 (2003): 1017-1021.
  36. Boltin D., et al. “European Registry on Helicobacter pylori management (Hp-EuReg): First-line Therapy in Israel”. The Israel Medical Association Journal: IMAJ1 (2021): 38-42.
  37. Lamouliatte H., et al. “Double vs single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia”. Alimentary Pharmacology and Therapeutics 13 (1999): 1523-1530.
  38. Vallve M., et al. “Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta‐analysis”. Alimentary Pharmacology and Therapeutics6 (2002): 1149-1156.
  39. Fossmark R., et al. “Adverse effects of proton pump inhibitors-Evidence and plausibility”. International Journal of Molecular Sciences20 (2019): 5203.
  40. Nehra AK., et al. “Proton pump inhibitors: review of emerging concerns”. In Mayo Clinic Proceedings2 (2018): 240-246.
  41. Yang Y., et al. “Proton-pump inhibitors use, and risk of acute kidney injury: a meta-analysis of observational studies”. Drug Design, Development and Therapy 11
    (2017): 1291.
  42. Randel A. “H. pylori infection: ACG updates treatment recommendations”. American family physician2 (2018): 135-137.
  43. Howden CW., et al. “Practice patterns for managing Helicobacter pylori infection and upper gastrointestinal symptoms”. American Journal of Managed Care 13.1 (2007): 37.
  44. AY EP and AE JC. “How do gastroenterologists in Peru deal with Helicobacter pylori infection? Study based on a survey conducted in 2014”. Revista de gastroenterologia del Peru: organo oficial de la Sociedad de Gastroenterologia del Peru4 (2015): 295-305.
  45. Wermeille J., et al. “Failure of Helicobacter pylori eradication: is poor compliance the main cause?” Gastroentérologie Clinique et Biologique3 (2002): 216-219.
  46. Graham DY., et al. “Factors influencing the eradication of Helicobacter pylori with triple therapy”. Gastroenterology2 (1992): 493-496.
  47. Lee M., et al. “A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy”. Archives of Internal Medicine19 (1999): 2312-2316.
  48. O'Connor JP., et al. “Improving compliance with Helicobacter pylori eradication therapy: when and how?” Therapeutic Advances in Gastroenterology5 (2009): 273-279.
  49. Brown MT., et al. “Medication adherence: truth and consequences”. The American Journal of the Medical Sciences4 (2016): 387-399.
  50. Shah SC., et al. “AGA Clinical Practice Update on The Management of Refractory Helicobacter pylori Infection: Expert Review”. Gastroenterology (2021).
  51. Al‐Eidan FA., et al. “Management of Helicobacter pylori eradication–the influence of structured counselling and follow‐up”. British Journal of Clinical Pharmacology2 (2002): 163-171.
  52. Banait G., et al. “Modifying dyspepsia management in primary care: a cluster randomised controlled trial of educational outreach compared with passive guideline dissemination”. British Journal of General Practice487 (2003): 94-100.
  53. Noya H., et al. “Do urea breath test (UBT) referrals for Helicobacter pylori testing match the clinical guidelines in primary care practice? A prospective observational study”. Journal of Evaluation in Clinical Practice5 (2008): 799-802.
  54. O'Connor HJ. “Helicobacter pylori and dyspepsia: physicians' attitudes, clinical practice, and prescribing habits”. Alimentary Pharmacology and Therapeutics3 (2002): 487-496.
  55. O’Connor A and O’Moráin C. “Mistakes in the management of Helicobacter pylori infection and how to avoid them”. Mistakes in…. (2017): 17.
Citation: Sarush Ahmed Siddiqui., et al. “Common Errors in H. Pylori Management - Recommendations for an Improved Practice”. EC Gastroenterology and Digestive System 9.6 (2022): 16-25.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


November Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the November issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for Upcoming Issue

ECronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before December 15, 2022.

Certificate of Publication

ECronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

ECronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.